Sugi Predict

Sugi Predict / Compounds / SCHEMBL1558099

SCHEMBL1558099

SCHEMBL1558099

CN1CCC(n2cc([N+](=O)[O-])cn2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT6 Q8N6T7 1/20 0.40
▸ ALOX15 P16050 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ BMPR1A P36894 1/20 0.37
▸ ACVRL1 P37023 1/20 0.37
▸ ACVR1 Q04771 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ GSK3B P49841 2/20 0.36
▸ DYRK1A Q13627 2/20 0.36
▸ WNT1 P04628 1/20 0.36
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ IKBKE Q14164 1/20 0.36
▸ TBK1 Q9UHD2 1/20 0.36
▸ CLK2 P49760 1/20 0.36
▸ CLK3 P49761 1/20 0.36
▸ PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15244435 0.94 MEN1 (0.39) SIRT6ALOX15ALDH1A1L3MBTL1BMPR1A
SCHEMBL1703008 0.92 ALOX15 (0.39) SIRT6ALOX15ALDH1A1L3MBTL1BMPR1A
SCHEMBL9952208 0.91 ALDH1A1 (0.36) SIRT6ALOX15ALDH1A1L3MBTL1ACHE
SCHEMBL31361661 0.91 ALDH1A1 (0.36) SIRT6ALOX15ALDH1A1L3MBTL1ACHE
SCHEMBL174612 0.87 F2 (0.41) ALDH1A1L3MBTL1ACHEMAPT
SCHEMBL16196214 0.85 MEN1 (0.42) ALDH1A1L3MBTL1ACHEMAPTGSK3B
SCHEMBL25238457 0.84 F2 (0.37) SIRT6ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL21296416 0.84 HRH3 (0.39) ALDH1A1MAPTGSK3BDYRK1ATBK1
SCHEMBL22648384 0.84 ALDH1A1 (0.40) ALDH1A1L3MBTL1ACHEMAPTGSK3B
SCHEMBL16975385 0.84 ACHE (0.45) ALDH1A1L3MBTL1ACHEMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745131-A1 PYRIMIDINAMINE NUAK INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF Technoderma Medicines Inc. (CN) 2026-05-20 — — EP disclosed
US-12630530-B2 FGFR inhibitor compound and use thereof HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2026-05-19 — — US disclosed
US-20260116887-A1 HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) 2026-04-30 — — US disclosed
US-12606544-B2 JAK1 selective kinase inhibitor DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2026-04-21 — — US disclosed
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 — — EP disclosed
US-12448382-B2 Heterocyclic compounds for mediating tyrosine kinase 2 activity GUANGZHOU INNOCARE PHARMA TECH CO. LTD. (CN) 2025-10-21 — — US disclosed
EP-3956322-B1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-05-14 — — EP disclosed
CN-115023428-B Pyrimidopyrroles compounds 江苏先声药业有限公司 2025-04-08 — — CN disclosed
CN-119707835-A 2-Aminopyrimidine-5-carboxamide compounds and use thereof for the production of medicaments for the treatment and/or prophylaxis of cancer 沈阳药科大学 2025-03-28 — — CN disclosed
EP-4504730-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 Dana-Farber Cancer Institute, Inc. (US) 2025-02-12 — — EP disclosed
EP-2303861-B1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2014-04-23 — — EP disclosed
US-8569298-B2 Pyridine compounds ASTRAZENECA AB (SE) 2013-10-29 — — US disclosed
US-8426408-B2 Pyrimidine inhibitors of kinases ABBVIE INC. (US) 2013-04-23 — — US disclosed
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 — — EP disclosed
CN-102124000-A Pyridine compounds ASTRAZENECA AB 2011-07-13 — — CN disclosed
US-20110166139-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2011-07-07 — — US disclosed
EP-2303861-A1 PYRIDINE COMPOUNDS AstraZeneca AB (SE) 2011-04-06 — — EP disclosed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 — — US disclosed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 — — WO disclosed
WO-2009153589-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB SIRT6 2255/4885ALOX15 3879/4885ALDH1A1 899/4885
US-12630530-B2 FGFR inhibitor compound and use thereof FGFR3, FGFR1, FGFR4 SIRT6 2308/4885ALOX15 2773/4885ALDH1A1 1323/4885
US-20260116887-A1 HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY TYK2, JAK2, JAK1 SIRT6 1205/4885ALOX15 4120/4885ALDH1A1 4108/4885
US-12606544-B2 JAK1 selective kinase inhibitor JAK1, JAK2, JAK3 SIRT6 1622/4885ALOX15 994/4885ALDH1A1 1845/4885
US-12448382-B2 Heterocyclic compounds for mediating tyrosine kinase 2 activity TYK2, JAK2, JAK1 SIRT6 1693/4885ALOX15 1094/4885ALDH1A1 3635/4885
US-20110166139-A1 PYRIDINE COMPOUNDS PTK2, PTK2B, PFKP SIRT6 1258/4885ALOX15 1957/4885ALDH1A1 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.